[Prerequisite and organisation of health-care pathways for Cell and Gene therapies, using Mesenchymal Stromal Cells (MSC) or Chimeric Antigen Receptor (CAR) T cells, in patients with autoimmune systemic diseases].
Castilla-Llorente C, Bonnin A, Lansiaux P, Tudesq JJ, Beuvon C, Fabreguettes JR, Pers YM, Pugnet G, Maria ATJ, Puyade M, Urbain F, Terriou L, Poindron V, Jachiet M, Cacciatore C, Lescoat A, Prata PH, Munia I, Madelaine I, Thieblemont C, Tarte K, Yakoub-Agha I, Magro L, Farge D, Marjanovic Z.
Castilla-Llorente C, et al. Among authors: lansiaux p.
Bull Cancer. 2024 Sep 5:S0007-4551(24)00267-4. doi: 10.1016/j.bulcan.2024.06.008. Online ahead of print.
Bull Cancer. 2024.
PMID: 39242251
Free article.
French.